Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Comparative Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of 188-0551 Spray Versus Reference Listed Drug (RLD) Applied Every 12 Hours for 2 Weeks in Subjects With Moderate to Severe Plaque Psoriasis

NCT04080206 is registered in ClinicalTrials.gov with Therapeutics, Inc. as lead sponsor.

NCT NCT04080206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04080206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Comparative Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of 188-0551 Spray Versus Reference Listed Drug (RLD) Applied Every 12 Hours for 2 Weeks in Subjects With Moderate to Severe Plaque Psoriasis
Lead sponsor
Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 7, 2020
Completion date
January 20, 2021
Enrollment
55 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis